Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure

Summary

To investigate whether an early supported discharge strategy for patients admitted to hospital because of HF, using a pH neutral subcutaneous (SC) furosemide formulation (SQINFurosemide) at home (delivered by non-CE marked SQINInfusor), compared to a usual care strategy with intravenous (IV) furosemide in hospital, results in an increased number of days spent alive and out of hospital (DAOH) at 30 days.

Timeline

Start

2022-11-17

Primary completion

2026-03-01

Completion

2026-03-01

Publications

• Campbell RT, Osmanska J, Docherty KF, Ahmed FZ, Clark AL, Clayton L, Cleland JGF, Critoph C, Dewhurst M, Hartshorne-Evans N, Gardner RS, Gatenby KV, Guha K, Kalra PR, Lees A, McConnachie A, Muntendam P, Mowat K, O'Donnell J, Placzek A, Ray R, Savage HO, Schiff R, Squire I, Wetherall K, Wong K, Wong C, McMurray JJV, Petrie MC. SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart Failure. Eur J Heart Fail. 2026 May 2;28(1):121-129. doi: 10.1093/ejhf/xuaf018.

Drugs

Indications